Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- MNPR
- Price
- 54.22
- Stock movement down
- -1.25 (-2.24%)
- Company name
- Monopar Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 362.30M
- Ent value
- 237.26M
- Price/Sales
- -
- Price/Book
- 2.56
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 28.35%
- 1 year return (CAGR)
- 21.34%
- 3 year return (CAGR)
- 42.73%
- 5 year return (CAGR)
- 4.50%
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MNPR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 2.56 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 6.68M |
| EPS (TTM) | -2.73 |
| FCF per share (TTM) | -1.52 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -21.62M |
| Net income (TTM) | -19.44M |
| EPS (TTM) | -2.73 |
| EPS (1y forward) | -3.48 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 127.68M |
| Net receivables | 0.00 |
| Total current assets | 144.09M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 106.67K |
| Total assets | 144.20M |
| Accounts payable | 2.54M |
| Short/Current long term debt | 102.24K |
| Total current liabilities | 2.57M |
| Total liabilities | 2.64M |
| Shareholder's equity | 141.56M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -10.83M |
| Capital expenditures (TTM) | 7.00 |
| Free cash flow (TTM) | -10.83M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -13.73% |
| Return on Assets | -13.48% |
| Return on Invested Capital | -13.73% |
| Cash Return on Invested Capital | -7.65% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 55.04 |
| Daily high | 55.74 |
| Daily low | 51.11 |
| Daily Volume | 154K |
| All-time high | 135.00 |
| 1y analyst estimate | 112.00 |
| Beta | 1.57 |
| EPS (TTM) | -2.73 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| MNPR | S&P500 | |
| Current price drop from All-time high | -59.84% | -1.82% |
| Highest price drop | -98.93% | -56.47% |
| Date of highest drop | 20 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -81.45% | -10.84% |
| Avg time to new high | 774 days | 12 days |
| Max time to new high | 1546 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
362.30M
Marketcap category
Small-cap
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Employees
14
Website
Investor relations
-
SEC filings
CEO
Chandler Drew Robinson
Country
USA
City
Wilmette
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page